Bruker (BRKR) Tops Q3 EPS by 6c
Bruker (NASDAQ: BRKR) reported Q3 EPS of $0.19, $0.06 better than the analyst estimate of $0.13. Revenue for the quarter came in at $396.1 million versus the consensus estimate of $373.65 million.
Bruker sees FY2015 EPS of $0.75-$0.80, versus the consensus of $0.75.
“We reported significantly higher organic revenue growth, profitability and free cash flow in the third quarter of 2015 as a result of stronger performance by our BioSpin and CALID Groups,” said Frank Laukien, President & CEO of Bruker. “In addition to healthy organic revenue growth and margin expansion in many of our divisions, our third quarter 2015 also benefited from favorable product mix and some earlier customer acceptances, which were originally not expected until our fourth quarter. As a result, our full year 2015 performance will be less dependent on our fourth quarter results than we previously forecasted.”
For earnings history and earnings-related data on Bruker (BRKR) click here.